On 3 April 2020, Medicines Australia (MA) and the Generic and Biosimilar Medicines Association (GBMA) were granted ACCC Authorisation to permit discussions and the implementation of strategies that support the continued supply of essential medicines and associated supplies to Australians, including those urgently needed for the treatment of COVID-19.
This authorisation reflects the critical need to stabilise and manage the supply of medicines which has seen unprecedented demand in recent weeks resulting from the COVID-19 pandemic.
Maintaining the supply of essential medicines to Australians who rely on them is the industry’s utmost priority as we face one of the biggest global health challenges of our time.
The details outlined by the ACCC provide specific guidelines around the sharing and exchange of information relating to the supply of prescription medicines together with general arrangements and agreements.
The links below provide further detail on the Authorisation including guidance on what is permitted when engaging with any other member of the MA/GBMA Working Group, and where legal advice is required before proceeding, to ensure there is no breach of the Competition and Consumer Act 2010 (Cth)
For further information, please contact Peter Komocki, Manager, Industry and Regulatory Policy at Medicines Australia.